Qiagen (NYSE:QGEN) issued an update on its FY 2020
Pre-Market earnings guidance on Monday morning. The company provided EPS guidance of 2.00 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.65. The company issued revenue guidance of $1.76-1.805 billion, compared to the consensus revenue estimate of $1.64 billion.Qiagen also updated its FY20 guidance to at least $2.00 EPS.
Shares of QGEN stock opened at $45.23 on Tuesday. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.41 and a current ratio of 1.58. Qiagen has a fifty-two week low of $25.04 and a fifty-two week high of $45.95. The stock has a 50 day moving average price of $43.36 and a two-hundred day moving average price of $39.50. The company has a market capitalization of $10.32 billion, a P/E ratio of -282.69, a PEG ratio of 2.14 and a beta of 0.32.
Qiagen (NYSE:QGEN) last announced its quarterly earnings data on Wednesday, May 6th. The company reported $0.34 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.27 by $0.07. Qiagen had a positive return on equity of 13.80% and a negative net margin of 2.01%. The firm had revenue of $372.10 million during the quarter, compared to the consensus estimate of $342.71 million. During the same quarter in the previous year, the company posted $0.27 earnings per share. The business’s revenue was up 6.7% on a year-over-year basis. As a group, equities analysts predict that Qiagen will post 1.74 earnings per share for the current year.
QGEN has been the subject of several recent research reports. Kepler Capital Markets reiterated a hold rating on shares of Qiagen in a research report on Wednesday, March 25th. DZ Bank reiterated a neutral rating on shares of Qiagen in a research report on Friday, May 29th. Stifel Nicolaus upped their target price on Qiagen from $33.00 to $40.00 and gave the company a hold rating in a report on Thursday, April 2nd. Finally, Warburg Research restated a neutral rating on shares of Qiagen in a report on Tuesday, June 23rd. One investment analyst has rated the stock with a sell rating, fifteen have issued a hold rating and five have assigned a buy rating to the company. The company currently has a consensus rating of Hold and a consensus target price of $37.54.
QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers sample technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, target enrichment, and library preparation for sequencing applications; and assay technology solutions.
Read More: 12b-1 Fees
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.